The goal is to generate DNA-encoded library (DEL) screening data for large numbers of under-addressed proteins in the human proteome — ultimately all...
The alliance will address clinical research and practice challenges related to data quality Enabled through the Syntropy and Evidium platforms, their ca...
Charles River Laboratories International, Inc. announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™. The pl...
Launch of Pin-pointTM base editing reagents improves access to new-generation editing technology Access to the Pin-point system now bridges discovery, p...
New sites at Darmstadt and Hamburg complement Merck’s global integrated mRNA service network with pre-clinical to commercial capabilities Company&...
Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, tod...
MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the Universit...
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...
“We are thrilled to receive marketing approval for AVT04 in Japan, which will be Alvotech’s second marketed biosimilar,” said Robert Wess...
Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational ...
QIAGEN announced the extension of its eco-friendlier QIAwave product line with the addition of two new nucleic acid extraction kits: the QIAwave RNeasy Plu...
In the world of biotechnology and pharmaceuticals, innovation is the lifeblood of progress. And in the picturesque Basel area, this spirit of innovation is...
The healthcare landscape in Latin America is currently a worldwide priority. Factors such as increasing awareness of precision medicine, the growing preval...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluatin...
© 2025 Biopharma Boardroom. All Rights Reserved.
